Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Continues To Refocus Marketing By Outsourcing Cefzil And Tequin

This article was originally published in The Pink Sheet Daily

Executive Summary

Ventiv will commit 375 reps to focus on the primary care market while Bristol will continue to sell the antibiotics to specialists in hospitals. The two companies had terminated a previous co-promotion agreement for Cefzil; the new contract is fee-for-service and does not include risk sharing.
Advertisement

Related Content

Rumors Of Big Pharma Sales Force Cuts Could Boost Smaller Contracts For Ventiv
Rumors Of Big Pharma Sales Force Cuts Could Boost Smaller Contracts For Ventiv
Primary Care Sales Force Downsizing Will Continue, Bristol Says
Primary Care Sales Force Downsizing Will Continue, Bristol Says
Merck Gets Second Chance On Dual PPAR: Will Co-Develop Bristol's Muraglitazar

Topics

Advertisement
UsernamePublicRestriction

Register

PS061016

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel